Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?

Derick H Lau, Linlang Guo, David R Gandara, Lawrence J T Young, Ling Xue

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

It has been speculated that weekly paclitaxel enhances antiangiogenesis and, hence, results in a greater inhibition of cancer growth than the 3-week schedule. We compared the weekly and 3-week schedules of paclitaxel in inhibiting angiogenesis, tumor growth and bone marrow hematopoiesis in a lung cancer model. Vehicle or paclitaxel was administered i.p. to three groups of nude mice bearing a human lung cancer. The vehicle was given weekly for six doses or every 3 weeks for two doses (Group A). Paclitaxel was administered at 20 mg/kg/week for six doses (Group B) or 60 mg/kg/3 weeks for two doses (Group C). The tumor growth rate was reduced by 50% equally in both the paclitaxel-treated groups. Intratumoral microvasculature was reduced by 70% in each paclitaxel-treated group. However, white blood cell count was significantly reduced in Group C in comparison with that of Group A or B. We conclude that in this model, angiogenesis and tumor growth were inhibited to the same extent when paclitaxel was administered on a weekly or 3-week schedule. Inhibition of tumor growth by paclitaxel was associated with suppression of angiogenesis. Weekly administration of paclitaxel resulted in a lower degree of leukopenia than with the 3-week schedule, mimicking the clinical setting.

Original languageEnglish (US)
Pages (from-to)871-875
Number of pages5
JournalAnti-Cancer Drugs
Volume15
Issue number9
DOIs
StatePublished - Oct 2004

Fingerprint

Paclitaxel
Appointments and Schedules
Growth
Neoplasms
Lung Neoplasms
Hematopoiesis
Leukopenia
Microvessels
Leukocyte Count
Nude Mice
Bone Marrow

Keywords

  • Antiangiogenesis
  • Dosing schedules
  • Paclitaxel

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? / Lau, Derick H; Guo, Linlang; Gandara, David R; Young, Lawrence J T; Xue, Ling.

In: Anti-Cancer Drugs, Vol. 15, No. 9, 10.2004, p. 871-875.

Research output: Contribution to journalArticle

Lau, Derick H ; Guo, Linlang ; Gandara, David R ; Young, Lawrence J T ; Xue, Ling. / Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?. In: Anti-Cancer Drugs. 2004 ; Vol. 15, No. 9. pp. 871-875.
@article{3cd2315231d447c2a85d2f50896790a8,
title = "Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?",
abstract = "It has been speculated that weekly paclitaxel enhances antiangiogenesis and, hence, results in a greater inhibition of cancer growth than the 3-week schedule. We compared the weekly and 3-week schedules of paclitaxel in inhibiting angiogenesis, tumor growth and bone marrow hematopoiesis in a lung cancer model. Vehicle or paclitaxel was administered i.p. to three groups of nude mice bearing a human lung cancer. The vehicle was given weekly for six doses or every 3 weeks for two doses (Group A). Paclitaxel was administered at 20 mg/kg/week for six doses (Group B) or 60 mg/kg/3 weeks for two doses (Group C). The tumor growth rate was reduced by 50{\%} equally in both the paclitaxel-treated groups. Intratumoral microvasculature was reduced by 70{\%} in each paclitaxel-treated group. However, white blood cell count was significantly reduced in Group C in comparison with that of Group A or B. We conclude that in this model, angiogenesis and tumor growth were inhibited to the same extent when paclitaxel was administered on a weekly or 3-week schedule. Inhibition of tumor growth by paclitaxel was associated with suppression of angiogenesis. Weekly administration of paclitaxel resulted in a lower degree of leukopenia than with the 3-week schedule, mimicking the clinical setting.",
keywords = "Antiangiogenesis, Dosing schedules, Paclitaxel",
author = "Lau, {Derick H} and Linlang Guo and Gandara, {David R} and Young, {Lawrence J T} and Ling Xue",
year = "2004",
month = "10",
doi = "10.1097/00001813-200410000-00007",
language = "English (US)",
volume = "15",
pages = "871--875",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?

AU - Lau, Derick H

AU - Guo, Linlang

AU - Gandara, David R

AU - Young, Lawrence J T

AU - Xue, Ling

PY - 2004/10

Y1 - 2004/10

N2 - It has been speculated that weekly paclitaxel enhances antiangiogenesis and, hence, results in a greater inhibition of cancer growth than the 3-week schedule. We compared the weekly and 3-week schedules of paclitaxel in inhibiting angiogenesis, tumor growth and bone marrow hematopoiesis in a lung cancer model. Vehicle or paclitaxel was administered i.p. to three groups of nude mice bearing a human lung cancer. The vehicle was given weekly for six doses or every 3 weeks for two doses (Group A). Paclitaxel was administered at 20 mg/kg/week for six doses (Group B) or 60 mg/kg/3 weeks for two doses (Group C). The tumor growth rate was reduced by 50% equally in both the paclitaxel-treated groups. Intratumoral microvasculature was reduced by 70% in each paclitaxel-treated group. However, white blood cell count was significantly reduced in Group C in comparison with that of Group A or B. We conclude that in this model, angiogenesis and tumor growth were inhibited to the same extent when paclitaxel was administered on a weekly or 3-week schedule. Inhibition of tumor growth by paclitaxel was associated with suppression of angiogenesis. Weekly administration of paclitaxel resulted in a lower degree of leukopenia than with the 3-week schedule, mimicking the clinical setting.

AB - It has been speculated that weekly paclitaxel enhances antiangiogenesis and, hence, results in a greater inhibition of cancer growth than the 3-week schedule. We compared the weekly and 3-week schedules of paclitaxel in inhibiting angiogenesis, tumor growth and bone marrow hematopoiesis in a lung cancer model. Vehicle or paclitaxel was administered i.p. to three groups of nude mice bearing a human lung cancer. The vehicle was given weekly for six doses or every 3 weeks for two doses (Group A). Paclitaxel was administered at 20 mg/kg/week for six doses (Group B) or 60 mg/kg/3 weeks for two doses (Group C). The tumor growth rate was reduced by 50% equally in both the paclitaxel-treated groups. Intratumoral microvasculature was reduced by 70% in each paclitaxel-treated group. However, white blood cell count was significantly reduced in Group C in comparison with that of Group A or B. We conclude that in this model, angiogenesis and tumor growth were inhibited to the same extent when paclitaxel was administered on a weekly or 3-week schedule. Inhibition of tumor growth by paclitaxel was associated with suppression of angiogenesis. Weekly administration of paclitaxel resulted in a lower degree of leukopenia than with the 3-week schedule, mimicking the clinical setting.

KW - Antiangiogenesis

KW - Dosing schedules

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=8344227715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8344227715&partnerID=8YFLogxK

U2 - 10.1097/00001813-200410000-00007

DO - 10.1097/00001813-200410000-00007

M3 - Article

C2 - 15457127

AN - SCOPUS:8344227715

VL - 15

SP - 871

EP - 875

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 9

ER -